Natalie Grinshtein
Director - ADC Biology & Oncology Pfizer
Natalie Grinshtein is the Director of ADC Biology at Pfizer, with over 20 years of experience in oncology and 8+ years in the industry. She is an immunologist and tumor biologist by training, with broad expertise in target discovery, ADCs, radioligands, cancer biology and drug discovery. Natalie has worked in Director roles in various environments, including Fusion Pharmaceuticals, Seagen, and currently Pfizer Oncology. She is passionate about early discovery research and leading a team of scientists to identify novel cancer treatments. Outside of work, Natalie is an avid hiker and nature lover.
Seminars
As the ADC landscape become increasingly crowded around established payload mechanisms and targets, leveraging chemistry and technological innovation is crucial to pursue novel ADC payloads and targeting moieties to develop differentiated ADCs that provide long-term patient benefit
Join this popular seminar day to stay ahead of the ADC design curve across discovery and performance of non-cytotoxic payloads, bispecific and fragment-conjugates, and dual payload ADCs
